Oncology Exchange: Evidence-based Management of Metastatic Colorectal Cancer

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: May 28, 2014          Expiration Date: May 28, 2015



By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.



This program is part of a series of associated Oncology Exchange programs; Click Here for information.

Program Description


The treatment armamentarium for mCRC has expanded significantly with the recent approval of several novel therapies. These advances have led to a widening of the gap between evidence-based practice guidelines and the practice patterns of community oncologists and other health care professionals who treat patients with mCRC.

Evidence-based Management of Metastatic Colorectal Cancer is designed to educate oncologists on the recent practice-changing data from ongoing clinical studies and to provide guidance on integrating evidence-based novel therapies into their clinical practices.


ADDITIONAL PATIENT RESOURCES


Download (PDF) Frankly Speaking about Cancer: Colorectal Cancer
Download (PDF) Newly Diagnosed: Fight Colorectal Cancer
Download (PDF) Colorectal Cancer Risk Factors and Symptoms
Download (PDF) Colorectal Cancer Screening

Faculty


AXEL GROTHEY, MD
Professor of Oncology
Mayo Clinic College of Medicine
Rochester, MN

Read Biography

JOHN L. MARSHALL, MD
Chief, Hematology and Oncology
Professor of Medicine and Oncology
Associate Director of Clinical Research
Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Read Biography


Target Audience


This activity is intended for community-based medical oncologists, surgical oncologists, radiation oncologists, and other health care professionals involved in the care of patients with mCRC.


Educational Objectives


At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Assess emerging evidence supporting the role of prognostic and predictive markers for personalized treatment planning in mCRC
  • Discuss updated clinical guidelines and the integration of newly approved agents into mCRC treatment planning
  • Review evidence-based data for patients with mCRC beyond progression

Accreditation


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.


Designation Statement


The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding this activity, please email contact@rockpointe-pcme.com.


DISCLOSURE INFORMATION


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty/steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Axel Grothey, MD: Research: Bayer, Daiichi-Sankyo, Eisai/Morphotek, Genentech, Sanofi

John L. Marshall, MD: Speaker: Amgen, Bayer/Onyx, Genentech

Non-faculty Content Contributors:
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Latha Shivakumar, PhD, CCMEP; Blair St. Amand; Jay Katz, CCMEP: Nothing to disclose

Robin K. Kelley, MD: Research: Celgene, Eli Lilly, Exelixis, Regeneron, Advisory Board: Acceleron, Eli Lilly


FDA Disclosure


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


System Requirements


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT


There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test by obtaining a score of 75%. Participant is allowed to take the post-test three times.


JOINTLY PROVIDED BY


Potomac Center for Medical Education and Rockpointe Oncology

Supported By


This activity is supported by an educational grant from Genentech.


By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.